[1] CHENG L, LI Y, XIA Q, et al. Enamel matrix derivative (EMD) enhances the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). Bioengineered. 2021;12(1):7033-7045.
[2] ZHU Y, YE L, CAI X, et al. Icariin-Loaded Hydrogel Regulates Bone Marrow Mesenchymal Stem Cell Chondrogenic Differentiation and Promotes Cartilage Repair in Osteoarthritis. Front Bioeng Biotechnol. 2022;10:755260.
[3] LIN W, CHEN Z, MO X, et al. Phactr1 negatively regulates bone mass by inhibiting osteogenesis and promoting adipogenesis of BMSCs via RhoA/ROCK2. J Mol Histol. 2022;53(1):119-131.
[4] ZHANG H, ZHANG W, BAI G, et al. Bone Morphogenetic Protein-7 (BMP-7) Promotes Neuronal Differentiation of Bone Marrow Mesenchymal Stem Cells (BMSCs) In Vitro. Biomed Res Int. 2021;2021(3):1-9.
[5] HANG HL, XIA Q. Role of BMSCs in liver regeneration and metastasis after hepatectomy. World J Gastroenterol. 2014;20(1):126-132.
[6] SUN C, ZHANG AD, CHEN HH, et al. Magnet-targeted delivery of bone marrow-derived mesenchymal stem cells improves therapeutic efficacy following hypoxic-ischemic brain injury. Neural Regen Res. 2021;16(11):2324-2329.
[7] LI YZ, LIU YJ, ZHANG W, et al. Combined treatment with valproic acid and estrogen has neuroprotective effects in ovariectomized mice with Alzheimer’s disease. Neural Regen Res. 2021;16(10):2078-2085.
[8] PITETZIS DA, SPILIOTI MG, YOVOS JG, et al. The effect of VPA on bone: From clinical studies to cell cultures-The molecular mechanisms revisited. Seizure. 2017;48:36-43.
[9] AKSHAYA N, PRASITH P, ABINAYA B, et al. Valproic acid, A Potential Inducer of Osteogenesis in Mouse Mesenchymal Stem Cells. Curr Mol Pharmacol. 2021;14(1):27-35.
[10] HAN W, GUAN W. Valproic Acid: A Promising Therapeutic Agent in Glioma Treatment. Front Oncol. 2021;11:687362.
[11] KITAZOE KI, ABE M, HIASA M, et al. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol. 2009; 89(1):45-57.
[12] SURAWEERA A, O’BYRNE KJ, RICHARD DJ. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front Oncol. 2018; 8:92.
[13] HUYNH NC, EVERTS V, AMPORNARAMVETH RS. Histone deacetylases and their roles in mineralized tissue regeneration. Bone Rep. 2017;7: 33-40.
[14] CHO HH, PARK HT, KIM YJ, et al. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem. 2005;96(3):533-542.
[15] CHA H, LEE J, PARK HH, et al. Direct Conversion of Human Fibroblasts into Osteoblasts Triggered by Histone Deacetylase Inhibitor Valproic Acid. Applied Sciences. 2020;10(20):7372.
[16] PAINO F, LA NOCE M, TIRINO V, et al. Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells. 2014;32(1):279-289.
[17] YU Y, OH SY, KIM HY, et al. Valproic Acid-Induced CCN1 Promotes Osteogenic Differentiation by Increasing CCN1 Protein Stability through HDAC1 Inhibition in Tonsil-Derived Mesenchymal Stem Cells. Cells. 2022;11(3):534.
[18] ZHOU D, CHEN YX, YIN JH, et al. Valproic acid prevents glucocorticoidinduced osteonecrosis of the femoral head of rats. Int J Mol Med. 2018;41(6):3433-3447.
[19] HUANG J, GOU H, YAO J, et al. The noncanonical role of EZH2 in cancer. Cancer Sci. 2021;112(4):1376-1382.
[20] PAPPAS K, MARTIN TC, WOLFE AL, et al. NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Commun Biol. 2021;4(1): 312.
[21] SAWICKA-GUTAJ N, SHAWKAT S, ANDRUSIEWICZ M, et al. EZH2 and SMYD3 expression in papillary thyroid cancer. Oncol Lett. 2021;21(5): 342.
[22] XIN L. EZH2 accompanies prostate cancer progression. Nat Cell Biol. 2021;23(9):934-936.
[23] LI C, SONG J, GUO Z, et al. EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment. Front Immunol. 2022;13:857808.
[24] GUI T, LIU M, YAO B, et al. TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer. Cell Death Differ. 2021;28(12):3316-3328.
[25] DUDAKOVIC A, CAMILLERI ET, PARADISE CR, et al. Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice. J Biol Chem. 2018;293(33):12894-12907.
[26] CHEN L, WU Y, WU Y, et al. The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/beta-catenin pathway. Sci Rep. 2016;6:29176.
[27] JING H, LIAO L, AN Y, et al. Suppression of EZH2 Prevents the Shift of Osteoporotic MSC Fate to Adipocyte and Enhances Bone Formation During Osteoporosis. Mol Ther. 2016;24(2):217-229.
[28] GALVAN ML, PARADISE CR, KUBROVA E, et al. Multiple pharmacological inhibitors targeting the epigenetic suppressor enhancer of zeste homolog 2 (Ezh2) accelerate osteoblast differentiation. Bone. 2021; 150:115993.
[29] DEDONI S, MARRAS L, OLIANAS MC, et al. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors. J Pharmacol Exp Ther. 2019;370(3):490-503.
[30] SAJADPOOR Z, AMINI-FARSANI Z, TEIMORI H, et al. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells. Appl Biochem Biotechnol. 2018;185(4):1132-1144.
[31] FU Y, ZHANG P, GE J, et al. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity. Int J Biochem Cell Biol. 2014;54:68-77.
[32] YI SJ, LEE H, LEE J, et al. Bone Remodeling: Histone Modifications as Fate Determinants of Bone Cell Differentiation. Int J Mol Sci. 2019; 20(13):3147.
[33] ICARDI L, DE BOSSCHER K, TAVERNIER J. The HAT/HDAC interplay: multilevel control of STAT signaling. Cytokine Growth Factor Rev. 2012; 23(6):283-291.
[34] VISHAL M, AJEETHA R, KEERTHANA R, et al. Regulation of Runx2 by Histone Deacetylases in Bone. Curr Protein Pept Sci. 2016;17(4):343-351.
[35] HSIEH TH, HSU CY, TSAI CF, et al. HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells. Mol Ther. 2015;23(4):656-666.
[36] PEREZ-CAMPO FM, SANTURTUN A, GARCIA-IBARBIA C, et al. Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone. Calcif Tissue Int. 2016;99(3):302-309.
[37] HEMMING S, CAKOUROS D, ISENMANN S, et al. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells. 2014;32(3):802-815.
[38] SEN B, PARADISE CR, XIE Z, et al. beta-Catenin Preserves the Stem State of Murine Bone Marrow Stromal Cells Through Activation of EZH2. J Bone Miner Res. 2020;35(6):1149-1162.
[39] DUDAKOVIC A, CAMILLERI ET, RIESTER SM, et al. Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice. J Biol Chem. 2016;291(47):24594-24606.
[40] ZHU L, XU PC. Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression. Biochem Biophys Res Commun. 2013;432(4):612-617.
|